Literature DB >> 31392143

Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?

Moritz Maas1, Arnulf Stenzl1.   

Abstract

Entities:  

Year:  2019        PMID: 31392143      PMCID: PMC6642982          DOI: 10.21037/tau.2019.03.03

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
  13 in total

1.  Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Patrick N Espiritu; Adrian S Fairey; Laura S Mertens; Colin P Dinney; Maria C Mir; Laura-Maria Krabbe; Michael S Cookson; Niels-Erik Jacobsen; Nilay M Gandhi; Joshua Griffin; Jeffrey S Montgomery; Nikhil Vasdev; Evan Y Yu; David Youssef; Evanguelos Xylinas; Nicholas J Campain; Wassim Kassouf; Marc A Dall'Era; Jo-An Seah; Cesar E Ercole; Simon Horenblas; Srikala S Sridhar; John S McGrath; Jonathan Aning; Shahrokh F Shariat; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeff M Holzbeierlein; Trinity J Bivalacqua; Scott North; Daniel A Barocas; Yair Lotan; Jorge A Garcia; Andrew J Stephenson; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black
Journal:  Eur Urol       Date:  2014-09-23       Impact factor: 20.096

2.  Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.

Authors:  Marco Moschini; Francesco Soria; Tobias Klatte; Gregory J Wirth; Mehmet Özsoy; Killian Gust; Alberto Briganti; Morgan Roupret; Martin Susani; Andrea Haitel; Shahrokh F Shariat
Journal:  Clin Genitourin Cancer       Date:  2016-07-22       Impact factor: 2.872

3.  Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.

Authors:  Robert S Svatek; Shahrokh F Shariat; Giacomo Novara; Eila C Skinner; Yves Fradet; Patrick J Bastian; Ashish M Kamat; Wassim Kassouf; Pierre I Karakiewicz; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Vincenzo Ficarra; Bjoern G Volkmer; Hendrik Isbarn; Colin P Dinney
Journal:  BJU Int       Date:  2011-01-18       Impact factor: 5.588

4.  Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.

Authors:  Polat Turker; Peter J Bostrom; Marcelo L Wroclawski; Bas van Rhijn; Hannes Kortekangas; Cynthia Kuk; Tuomas Mirtti; Neil E Fleshner; Michael A Jewett; Antonio Finelli; Theo Vander Kwast; Andy Evans; Joan Sweet; Matti Laato; Alexandre R Zlotta
Journal:  BJU Int       Date:  2012-02-09       Impact factor: 5.588

5.  Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.

Authors:  Achim Fleischmann; George N Thalmann; Aurel Perren; Roland Seiler
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

6.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; A Karim Kader; Adam S Kibel; Timothy M Kuzel; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Daniel Petrylak; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

7.  Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

Authors:  Stephen H Culp; Rian J Dickstein; H Barton Grossman; Shanna M Pretzsch; Sima Porten; Siamak Daneshmand; Jie Cai; Susan Groshen; Arlene Siefker-Radtke; Randall E Millikan; Bogdan Czerniak; Neema Navai; Matthew F Wszolek; Ashish M Kamat; Colin P N Dinney
Journal:  J Urol       Date:  2013-07-30       Impact factor: 7.450

8.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Authors:  J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal
Journal:  Eur Urol       Date:  2016-06-30       Impact factor: 20.096

9.  Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Authors:  Venkata K Pokuri; Johar R Syed; Zhengyu Yang; Erinn P Field; Susanna Cyriac; Roberto Pili; Ellis Glenn Levine; Gissou Azabdaftari; Donald L Trump; Khurshid Guru; Saby George
Journal:  Clin Genitourin Cancer       Date:  2015-10-03       Impact factor: 2.872

10.  Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.

Authors:  Friedrich-Carl von Rundstedt; Douglas A Mata; Oleksandr N Kryvenko; Anup A Shah; Iny Jhun; Seth P Lerner
Journal:  Bladder Cancer       Date:  2017-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.